These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35438536)

  • 1. The HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release.
    Tabler CO; Wegman SJ; Chen J; Shroff H; Alhusaini N; Tilton JC
    J Virol; 2022 May; 96(9):e0219821. PubMed ID: 35438536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premature Activation of the HIV-1 Protease Is Influenced by Polymorphisms in the Hinge Region.
    Tabler CO; Wegman SJ; Alhusaini N; Lee NF; Tilton JC
    Viruses; 2024 May; 16(6):. PubMed ID: 38932142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoscale flow cytometry reveals interpatient variability in HIV protease activity that correlates with viral infectivity and identifies drug-resistant viruses.
    Bonar MM; Tabler CO; Haqqani AA; Lapointe LE; Galiatsos JA; Joussef-Piña S; Quiñones-Mateu ME; Tilton JC
    Sci Rep; 2020 Oct; 10(1):18101. PubMed ID: 33093566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.
    Jochmans D; Anders M; Keuleers I; Smeulders L; Kräusslich HG; Kraus G; Müller B
    Retrovirology; 2010 Oct; 7():89. PubMed ID: 20950436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal.
    Trinité B; Zhang H; Levy DN
    Retrovirology; 2019 Jun; 16(1):17. PubMed ID: 31242909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Inhibition: A Novel Strategy of Targeting HIV-1 Protease to Eliminate Viral Reservoirs.
    Kim JG; Shan L
    Viruses; 2022 May; 14(6):. PubMed ID: 35746649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules.
    Wen J; Yan M; Liu Y; Li J; Xie Y; Lu Y; Kamata M; Chen IS
    PLoS One; 2016; 11(4):e0151572. PubMed ID: 27049645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
    Rochat MA; Schlaepfer E; Speck RF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
    Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
    Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
    Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.
    Rong L; Perelson AS
    PLoS Comput Biol; 2009 Oct; 5(10):e1000533. PubMed ID: 19834532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy.
    Wang S; Rong L
    J Theor Biol; 2014 Nov; 360():137-148. PubMed ID: 25016044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
    Ollerton MT; Berger EA; Connick E; Burton GF
    J Virol; 2020 May; 94(10):. PubMed ID: 32161179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
    J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.